Best RNS i've seen years....19 Jan 2026 18:40
Top 5 Positives – GDR Equity Support RNS
1/ Cornerstone backing de-risks the fundraise. Two major shareholders (David Nugent and Robert English) have pre-committed £3m (50% of the raise), materially reducing execution risk and signalling strong insider conviction at current prices.
2/ Pricing discipline – no desperation. The explicit statement that the raise would be “at or around the current share price (including higher)” removes the fear of a deeply discounted, dilutive raise — a key AIM sentiment driver.
3/ Loan converts to equity (non-predatory capital). Nugent converting the £500k loan into equity aligns interests, removes near-term balance-sheet risk, and confirms the loan was bridge capital, not leverage.
4/ Clear use of funds tied to value-creating milestones. Proceeds are earmarked for FDA 510(k) submission (mid-2026), manufacturing scale-up, and international expansion, all of which are tangible re-rating catalysts rather than “keeping the lights on”.
5/ Board and management alignment. Directors committing £100k+ of their own capital reinforces credibility and reduces the perception of asymmetric risk between insiders and shareholders.
Not to mention £6m is around 15 months funding, assuming monthly cash burn stays around £350,000-£400,000 as indicted in previous company communications.
GLA.
Stephen11.